Bayer’s $7.25B Roundup deal hits fresh court roadblock
Synopsis
Bayer’s proposed $7.25 billion Roundup settlement has hit another legal hurdle after objections delayed court proceedings in Missouri. The case remains closely watched across agricultural and legal sectors as Bayer continues managing billions in litigation costs tied to glyphosate-related cancer claims following its Monsanto acquisition.
Bayer’s proposed Roundup settlement faces court objections over future claimant protections as litigation costs continue impacting the company’s finances and long-running glyphosate-related legal disputes remain active.
Key Highlights
- Bayer’s $7.25 billion Roundup settlement faces new legal objections in Missouri court.
- Critics argue future claimants may unknowingly waive legal rights under the proposed agreement.
- Bayer has already paid around $11 billion in Roundup-related settlements and verdicts.
- Glyphosate remains approved in several major agricultural economies despite continuing legal disputes.
Bayer's proposed $7.25 billion settlement for Roundup is coming under fresh pressure as legal objections slowed down court proceedings related to future cancer claims from the weedkiller.
The new challenge follows on the heels of Bayer's ongoing battle with one of the largest product liability cases in the agricultural chemical business. The proposed deal, which was filed in the Missouri state court, would resolve future claims of non-Hodgkin lymphoma from those who could claim they were exposed to Roundup in the future.
According to court documents seen by Reuters and Bloomberg, several legal groups said the settlement could undermine their legal claims before they are aware of potential health issues.
Fresh Delay Adds to Bayer’s Legal Burden
The court was set to consider the settlement this week, but it has been stalled due to arguments concerning the notification procedure and the settlement's compensation arrangements.
The conflict comes at a time when Bayer acquired Monsanto in 2018 for approximately $63 billion. Since then, the company has paid approximately $11 billion to settle Roundup-related lawsuits and jury verdicts, and thousands of claims remain pending.
Glyphosate-based products are widely used in the most important agricultural markets in Canada, Brazil, Argentina, Australia and India, making Roundup litigation a hot topic in the agriculture, chemical and investment industries.
The use/glyphosate debate is still split
Bayer remains convinced glyphosate is safe if used properly. The company has cited studies by the U.S. Environmental Protection Agency and the European Food Safety Authority that have concluded that there is no sufficient evidence to prove glyphosate is a carcinogen when used as approved.
The legal fights, however, have escalated since the International Agency for Research on Cancer (IARC) categorised glyphosate as “probably carcinogenic” in 2015. This classification drew the focus of several Monsanto and eventually Bayer lawsuits.
The EU reapproved glyphosate for 10 more years in 2023, and a few countries, such as Luxembourg, implemented restrictions or phase-outs.
Litigation Costs Continue to Affect Financials
In its latest first quarter 2026 results, Bayer has posted 13.4 billion euros in sales and 2.76 billion euros in net income.
Litigation-related payments also had an impact on free cash flow during the quarter, Bayer said. Its ‘Crop Science' division, including Roundup products, had quarterly sales of 7.6 billion euros.
FAQs
Q1. Why is Bayer’s Roundup settlement facing court objections?
Legal groups argue the proposed deal could limit the rights of future cancer claimants before diagnoses are confirmed.
Q2. How much has Bayer spent on Roundup litigation so far?
Bayer has paid about $11 billion in settlements and verdicts tied to Roundup cancer lawsuits since acquiring Monsanto.
Q3. Is glyphosate still approved for use globally?
Yes. Glyphosate remains approved in major agricultural markets, though some countries have introduced restrictions or phase-out plans.
Follow Inspirepreneur Magazine for daily global business news.
Pooja Malik is a business journalist with over six years of experience covering startups, entrepreneurship, and emerging trends. She has previously worked with leading media platforms such as YourStory Media and BW BusinessWorld, where she reported on business, policy, and market developments. Currently, she serves as Editor at The Inspirepreneur Magazine, where she writes and edits stories across business, lifestyle, and travel, with a focus on clarity, accuracy, and reader relevance.
You Might Also Like
Zoe Foster Blake: The Journey from Beauty Editor to Skincare Mogul
Mubadala plans $1.91B stake sale in GlobalFoundries
